Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulodexide for Prevention of Psoriasis Recurrence
NCT06982196Phase 3Enrolling by invitation
- Sponsor
- Xijing Hospital
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sulodexide in psoriasis, sponsored by Xijing Hospital. Started Apr 2025; status: enrolling by invitation.
02
Drugs
sulodexide
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06982196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06982196.